Lisinopril in Black and African Ancestry Patients: Safety Profile Differences Explained
Lisinopril is an oral angiotensin-converting enzyme (ACE) inhibitor, sold under brand names including Prinivil and Zestril, approved by the FDA for hypertension, heart failure, and reduction of mortality after acute myocardial infarction. It is not the same drug as an angiotensin receptor blocker (ARB) such as losartan, and it should not be confused with combination products that pair lisinopril with hydrochlorothiazide.
Direct answer: In Black and African ancestry adults, published hypertension research and guideline bodies (including the 2017 ACC/AHA hypertension guideline) describe lisinopril and other ACE inhibitors as less effective at lowering blood pressure when used alone, compared with thiazide-type diuretics or calcium-channel blockers, and describe ACE-inhibitor angioedema as occurring more frequently in Black patients than in white patients. Neither finding means lisinopril is unsafe or should be withheld for all indications: in proteinuric chronic kidney disease, diabetic nephropathy, and heart failure with reduced ejection fraction, ACE inhibitors remain guideline-recommended regardless of ancestry. The exact magnitude of the angioedema and blood-pressure differences varies across the studies that report them, and readers should treat any single percentage with caution until it is checked against the primary paper.
This article distinguishes what is established from what is plausible but not settled, and flags where the original source citations behind commonly repeated numbers could not be verified for this draft.
A note on the numbers in this article
An earlier version of this page attached specific PubMed identifiers to precise statistics (exact percentages, incidence rate ratios, and a direct quotation from a guideline). On review, those identifiers could not be confirmed to point to the correct underlying papers, and a wrong citation is worse than none. This revision keeps the well-established qualitative findings, states numeric ranges as ranges reported in the literature rather than exact single figures, and marks anything that still needs primary-source verification. Editors should confirm any number before it appears in a patient-facing claim.
Why lisinopril's effect can differ by ancestry: the renin-angiotensin mechanism
ACE inhibitors lower blood pressure primarily by blocking conversion of angiotensin I to angiotensin II, and they raise bradykinin levels as a secondary effect of inhibiting the same enzyme (kininase II). Hypertension in Black populations, as a group, is more often described in the literature as low-renin and volume-dependent compared with hypertension in white populations. Because lisinopril interrupts an angiotensin-II-driven pathway, patients with lower renin activity as a group tend to see a smaller blood pressure drop from ACE inhibition used alone. This is a population-level tendency, not a rule that applies to any individual patient; renin status varies within every ancestry group, and it is not routinely measured before prescribing.
The ACE gene carries a well-studied insertion/deletion polymorphism that affects circulating ACE levels, and allele frequencies for this variant differ across ancestry groups. This is a plausible contributor to different average drug response, but it is not something used in routine clinical decision-making, and genotyping is not standard of care for choosing or dosing an antihypertensive.
The most serious safety signal: angioedema
Angioedema is the most serious adverse effect associated with ACE inhibitors, including lisinopril. It typically involves swelling of the lips, tongue, or throat, and the FDA label carries a boxed or highlighted warning about this reaction. The label also notes that angioedema can occur at any point during treatment, including after long periods of uneventful use, not only in the first days or weeks.
Observational research consistently documents elevated rates of ACE-inhibitor-induced angioedema among Black patients compared to white patients, with published estimates typically suggesting a several-fold increase in relative risk. Reported incidence rates and confidence intervals vary between individual studies and patient populations; any numerical values discussed here should be cross-referenced with primary literature before citation as definitive measurements. Across published studies, the pattern remains stable: Black patients show increased relative risk, supported by mechanistic evidence from bradykinin-degradation pathways, notably variants in genes like XPNPEP2 (encoding a bradykinin-metabolizing enzyme) that demonstrate ancestry-specific frequency distributions.
Clinical bottom line: any new swelling of the lips, tongue, face, or throat, or difficulty breathing or swallowing, in a patient taking lisinopril is a medical emergency. The drug should be stopped and emergency care sought immediately, regardless of how long the patient has been taking it.
Patients who have had ACE-inhibitor angioedema should generally not be rechallenged with any ACE inhibitor. Switching to an ARB is a reasonable alternative discussed in guidelines, since ARBs do not raise bradykinin the same way, though ARBs are not entirely free of angioedema risk either. This decision should be made with the prescribing clinician, not by the patient alone.
Blood pressure efficacy: what ALLHAT showed and did not show
The ALLHAT trial (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) was a large, government-funded, multi-arm trial comparing an ACE inhibitor (lisinopril), a calcium-channel blocker (amlodipine), and a thiazide-type diuretic (chlorthalidone) as first-step antihypertensive therapy. It included a substantial pre-specified Black participant subgroup. Subgroup analyses of ALLHAT are widely reported as showing that lisinopril performed worse than chlorthalidone for stroke prevention in Black participants, and that average blood pressure control was somewhat less tight in the lisinopril arm within that subgroup.
This finding is trial evidence, one of the higher tiers of evidence available, but the exact effect size (the precise percentage difference in stroke rate) attached to this claim in earlier drafts of this page could not be independently confirmed here and should be checked against the original 2002 JAMA publication before being quoted as a specific number in patient materials.
What ALLHAT does not show is that lisinopril is harmful in an absolute sense for Black patients. The comparison was head-to-head against a diuretic that performed better, not against no treatment. Lisinopril still reduced cardiovascular risk compared with untreated hypertension in general. The practical lesson guideline bodies have drawn from ALLHAT and related trials is a sequencing one: start with a thiazide-type diuretic or a calcium-channel blocker for uncomplicated hypertension in Black adults, and use an ACE inhibitor as an add-on or as first-line only when a specific indication (see below) favors it.
When lisinopril is still first-line regardless of ancestry
The picture changes for patients with proteinuric chronic kidney disease, diabetic nephropathy, or heart failure with reduced ejection fraction. In these conditions, ACE inhibitors (and ARBs) have a distinct, guideline-supported role in slowing kidney function decline and reducing heart failure hospitalizations and mortality, and current nephrology guidelines (including KDIGO recommendations on diabetes and CKD) support ACE inhibitor or ARB use for patients with significant albuminuria regardless of ancestry. The AASK trial (African American Study of Kidney Disease and Hypertension) specifically studied Black patients with hypertensive kidney disease and is frequently cited as showing an ACE inhibitor (ramipril) outperforming a calcium-channel blocker for slowing kidney function decline in this population; the exact numeric effect size again should be confirmed against the primary AASK publications before being used as a precise figure.
Because of this split, "should a Black patient take lisinopril" is the wrong question. The better question is "what is the indication," since the recommended first-line agent flips depending on whether the goal is uncomplicated blood pressure control or protection of already-damaged kidneys or a failing heart.
Current guideline recommendations for uncomplicated hypertension
The 2017 ACC/AHA hypertension guideline recommends a thiazide-type diuretic or a calcium-channel blocker as initial therapy for Black adults with hypertension who do not have heart failure or chronic kidney disease, including those with diabetes. This is a guideline recommendation, not a prohibition on ACE inhibitors: lisinopril remains an appropriate add-on agent if blood pressure is not controlled on a single first-line drug, and it becomes a preferred agent once CKD or heart failure with reduced ejection fraction is present. Readers should confirm the current version of this guideline, since hypertension guidance is periodically updated.
Other pharmacogenomic and clinical factors worth knowing
ACE-inhibitor cough. Dry cough is a known class effect of ACE inhibitors, related to bradykinin accumulation in the airway. It is commonly reported to occur somewhat more often in Black patients than in white patients, though published incidence ranges vary by study and should not be repeated as a single fixed percentage without checking the source. Persistent, bothersome cough is a reasonable and low-risk reason to switch to an ARB.
G6PD deficiency. G6PD deficiency is more common in Black populations, particularly among males. Lisinopril itself does not interact with G6PD and does not trigger hemolysis. The relevance is indirect: patients on lisinopril who are later prescribed drugs known to trigger hemolysis in G6PD deficiency, such as trimethoprim-sulfamethoxazole or dapsone, may need G6PD screening before starting those other drugs. This is a general prescribing safety point, not something specific to lisinopril's own pharmacology.
Pharmacokinetics. Lisinopril's absorption, elimination (renal, unchanged, no significant hepatic metabolism), and dosing adjustments for reduced kidney function are not described in the literature as differing meaningfully by ancestry. Dose adjustment should be driven by estimated glomerular filtration rate, not by race or ancestry.
Chronic kidney disease burden. CKD is more prevalent among Black Americans than white Americans according to CDC surveillance data, which is one reason hyperkalemia and renal function monitoring after starting lisinopril deserve particular attention in this population, independent of any drug-response difference (CDC Chronic Kidney Disease Surveillance data, reviewed periodically; verify current figures before citing a specific prevalence percentage).
Evidence and transferability map: what this actually rests on
| Claim | Directly studied in Black/African-ancestry populations | Extrapolated or uncertain | Needs specialist input before acting | Outcome to monitor |
|---|---|---|---|---|
| Lisinopril monotherapy produces smaller average BP reduction than thiazides/CCBs in Black adults | Yes, in large trials including ALLHAT subgroup analyses (exact effect size needs primary-source verification) | Whether this applies to an individual patient's actual renin status, which is not routinely tested | Primary care or cardiology if BP not at goal after a few weeks on a single agent | Home and clinic BP trend after 2 to 4 weeks on initial therapy |
| ACE-inhibitor angioedema occurs more often in Black patients | Yes, across multiple observational cohorts; direction of finding is consistent, exact incidence figures vary by study | The absolute risk for a given patient without known genetic risk markers | Emergency evaluation immediately if any facial, lip, tongue, or throat swelling occurs, regardless of ancestry | New swelling, voice change, or throat tightness at any point during treatment, not just early on |
| ACE inhibitors slow CKD progression more than CCBs in Black patients with hypertensive kidney disease | Yes, AASK trial specifically enrolled Black participants (exact numeric effect needs verification against the primary publication) | Whether the same magnitude of benefit applies outside the eGFR and albuminuria ranges studied | Nephrology involvement for CKD staging, ACE inhibitor initiation and titration, and potassium management | Serum creatinine, eGFR trend, and urine albumin-to-creatinine ratio |
| ACE gene polymorphism frequency differs by ancestry and may explain part of the response difference | Population allele-frequency data exist | Whether this translates into a clinically actionable prediction for an individual patient | Genotyping is not standard of care; do not order it to guide lisinopril dosing without specialist context | Not directly monitorable; treat as background mechanism, not a decision input |
| Lisinopril pharmacokinetics and dosing by renal function | Studied broadly, not shown to differ meaningfully by ancestry | None substantial identified in available sources | Nephrology or pharmacy consult for dose adjustment in advanced CKD | Serum creatinine/eGFR and potassium at baseline and after dose changes |
Monitoring after starting lisinopril
Baseline potassium and creatinine should be checked before starting lisinopril, then rechecked roughly one to two weeks after starting and after any dose increase, since ACE inhibitors can raise serum potassium and reduce eGFR modestly, an effect that is monitored the same way regardless of ancestry but carries somewhat higher stakes in populations with a higher baseline burden of CKD. Patients should be told explicitly, at the time of prescribing, what angioedema looks like and that it can appear at any time during treatment, not just in the first few weeks. A cough that develops after starting lisinopril is not dangerous but is a reasonable, low-risk reason to discuss switching to an ARB with the prescriber.
What is established, what is plausible, and what is not established
Established: ACE inhibitors carry a class-wide angioedema risk described on the FDA label; observational data consistently show higher relative angioedema risk in Black patients than in white patients; large trial evidence (ALLHAT) shows lisinopril monotherapy performing worse than chlorthalidone for stroke prevention in a Black subgroup; current U.S. hypertension guidelines recommend thiazides or calcium-channel blockers first for uncomplicated hypertension in Black adults; ACE inhibitors have a distinct, guideline-endorsed role in proteinuric CKD and heart failure with reduced ejection fraction regardless of ancestry.
Plausible but not settled for individual prediction: that specific gene variants (ACE I/D, XPNPEP2, BDKRB2) reliably predict which individual patient will develop angioedema, cough, or a blunted BP response. These are population-level associations from pharmacogenomic research, not validated clinical tests.
Not established from the material reviewed here: precise single-number incidence rates, incidence rate ratios, or trial effect sizes strong enough to state as fixed facts without checking the original publications. This draft intentionally avoids restating exact percentages that could not be traced to a verifiable primary source.
When to seek urgent care
Stop lisinopril and seek emergency care immediately for any swelling of the face, lips, tongue, or throat, difficulty breathing or swallowing, or a sudden hoarse voice, at any point during treatment. Contact the prescribing clinician promptly for a new, persistent dry cough, signs of very high or very low blood pressure, or symptoms of hyperkalemia such as muscle weakness or an irregular heartbeat. Do not adjust the dose or stop the medication for uncomplicated hypertension without discussing it with a clinician first, since abrupt discontinuation is not appropriate in patients being treated for heart failure or CKD.
References
- CDC Chronic Kidney Disease surveillance resources: https://www.cdc.gov/kidneydisease/publications-resources/2019-report.html
- ALLHAT (JAMA 2002) and AASK (JAMA 2002) are referenced by name as well-known trials; specific effect sizes attributed to them in earlier drafts of this page require verification against the original publications before reuse.